uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted April 17, 2020

Joint Pain Supplement Isoprex Settles Charges of Making False Claims

On April 16, 2020, Renaissance Health Publishing, LLC, agreed to halt their allegedly deceptive advertising claims about their Isoprex supplement that targeted older consumers nationwide after the Federal Trade Commission (FTC) filed a complaint. As part of the settlement, the company is barred from making false and unsubstantiated health claims about the products, and will pay $100,000.

According the FTC's complaint, Renaissance Health Publishing, LLC, sold Isoprex, a pill containing herbs and spices, through direct mail brochures and websites. These products were promoted with claims that they could treat or cure joint pain, muscle pain, headaches, and arthritis, but these claims were not supported by scientific evidence. The director of the FTC's Bureau of Consumer Protection warned, "When you target older adults with promises that your supplement will relieve pain better than FDA-approved drugs, you'd better have the scientific proof to back that up. For help with pain or other health conditions, people should rely on their medical professional, not on an advertisement." 

The proposed order bans Renaissance Health Publishing, LLC, from making claims about its products without competent and reliable scientific evidence. It also imposes a $3.93 million judgment against Renaissance Health Publishing, LLC, which will be partially suspended after they pay $100,000. These funds may be used to refund consumers who were harmed by the company's allegedly misleading claims.

See Related Recalls and Warnings:

Seller of Rejuvenation Pills Settles Charges of Making False Claims

Seller of TrueAloe and AloeCran Settles Charges of Making False Claims

Advocare to Pay $150 Million to Settle Charges of Operating a Pyramid Scheme

CVS Settles Lawsuit Over Claims Its Omega-3 Supplement Improves Memory

For more information, use the link below.